CURATIVe Flashcards

1
Q

What is the recommendation for antithrombotics in IMHA in dogs?

A

Antithrombotic therapy is recommended
- not enough evidence to recommend specific type or protocol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the suspected contributing causes of a hypercoagulable state in IMHA?

A
  • Increased TF expression
  • Platelet activation
  • Microparticle circulation
  • NET formation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the recommendation for antithrombotics in dogs with PLN?

A

Recommend antithrombotic therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What type of thromboembolic events most commonly occur in PLN?

A

PTEs

followed by ATEs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the recommendation for antithrombotic therapy in cats with IMHA?

A

suggest considering antithrombotic agents if other risk factors for thrombosis exist

weak evidence of risk of PTE
no evidence of increased risk of ATE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the recommendation for antithrombotic therapy in dogs with pancreatitis?

A

suggest to consider antithrombotic therapy in dogs with pancreatic NECROSIS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the recommendation for antithrombotic therapy in dogs receiving glucocorticoids?

A

suggest considering antithrombotics if other risk factors are present

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What body system is particularly prone to thrombosis during glucocorticoid administration?

A

portal vasculature

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the recommendation for antithrombotic therapy in cats receiving glucocorticoids?

A

antithrombotics should not be routinely administered

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the recommendation for antithrombotic therapy in dogs or cats with hyperadrenocorticism?

A

HAC alone does not warrant antithrombotic therapy unless other risk factors present

thrombosis only shown in a small subset of dogs with HAC

antithrombotics should not be routinely used in cats with HAC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What type of cancer is most associated with thrombosis in dogs?

A

Adenocarcinomas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the recommendation for antithrombotic therapy in dogs with cancer?

A

consider antithrombotics if hypercoagulability was demonstrated and other risk factors are present

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the recommendation for antithrombotic therapy in sepsis?

A

do not recommend routine use
consider use if risk fasctors present and hypercoagulability present
cats specifically - emphasize risk benefit assessment

overall low evidence of sepsis shown in cats and if it occured PTE most common

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the recommendation for antithrombotic therapy in cerebrovascular disease?

A

consider use if ischemic stroke identified and risk factor present

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the recommendation for antithrombotic therapy in dogs or cats with cardiac disease?

A
  • recommend use in cats with cardiomyopathy - particularly if: history of ATE, left atrial (LA) dilation, spontaneous echocontrast, or reduced LA appendage flow velocity
  • consider use in dogs where other risk factors are present - not a high risk otherwise
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the most common causes of ATE in dogs versus cats?

A

Cats - cardiomyopathy
Dogs - PLN, neoplasia, HAC

17
Q

Define what animals are considered at risk for thrombosis

A
  • dogs with PLN or IMHA
  • cats with cardiomyopathy if: Cats with a history of ATE, left atrial (LA) dilation, spontaneous echocontrast, or reduced LA appendage flow velocity
  • dogs or cats with more than one disease/risk factor

low moderate risk:
* only one risk factor
* known risk factor diseases that are expected to resolve

18
Q

What is the recommendation for antithrombotic therapy in dogs or cats with heartworm disease

A

recommend considering use
especially if severe disease or adulticide therapy administered

cats same and especially if other risk factors present

19
Q

What is the recommendation for antithrombotic therapy in cats with PLN?

A

suggest consideration only if other risk factors present

only weakly associated with venous thrombosis and no evidence that PLN in cats is a risk factor for ATE

20
Q

What is the recommendation for antithrombotic therapy in dogs or cats with liver disease?

A

cats: no recommendation made
dogs: recommend weighing risks and benefits and considering if other risk factors are present

21
Q

Where are dogs with hepatic disease most likely to develop thrombosis?

A

hepatic and splenic circulation

22
Q

What is the recommendation for antithrombotic therapy in dogs with PSS?

A

Note: risk mostly shown with attenuation/surgery of cPSS

In dogs undergoing PSS surgery: consider use after risk benefit assessment or if other risk factors present

Do not recommend routine use in cPSS

cats: against routine use but consider after risk benefit assessment or if other risk factors present

23
Q

What is the recommendation for antithrombotic therapy in dogs with cardiac arrhythmias?

A

if atrial fibrillation - consider use if other risk factors present (specific risk factors: reduced atrial appendage flow velocity or attempted cardioversion)
other arrhythmias - not recommedned to use

24
Q

What is the recommendation for antithrombotic therapy in cat with arrhythmias

A

recommend use in cats with arrhythmias and structural heart disease

25
What is the recommendation for antithrombotic therapy in dogs with PLE?
recommend use - unless risk factors outweight benefits cats: consider if other risk factors present
26
What is the recommendation for antithrombotic therapy in SA with venous or arterial catheters?
venous - consider if other risk factors present arterial - routine use not recommended
27
What is the recommendation for antithrombotic therapy in SA with vascular access ports?
dogs - cannot make an evidence-based recommendation cats - do not routinely use
28
What is the recommendation for antithrombotic use in dogs undergoing extracorporeal circuit use
* during use - recommended * inbetween - routine use not recommended cats - no recommendation made
29
What is the recommendation for antithrombotic therapy in dogs undergoing transvenous pacemaker palcement?
recommended if other risk factors present suggested in all dogs prevalence of thrombosis about 5% and 1% for symptomatic thrombosis
30
What is the recommendation for UFH versus LMWH use in dogs and cats?
LMWH preferred over UFH but just suggestion/not recommendation more reliable effects and better safety profile
31
What is the recommendation on Factor X inhibtors versus heparin?
Factor X inhibitors preferred over UFH but equally LMWH or Xa inhibitors can be considered
32
What is the recommendation for combination therapy (antiplatelet + anticoagulant)?
suggest combination for VTE or ATE depending on risk of thrombosis and if the risk of thrombosis outweighs the risk of bleeding
33
What is the recommendation for aspirin for ATE or VTE prevention in dogs or cats?
* ATE in dogs - may be efficacious — may take 2-3 days until fully effective * VTE in dogs - no recommendation made * ATE in cats - recommend against
34
How should a patient receiving aspirin be monitored?
can consider platelet function testing via aggregometry but insufficient evidence to make recommendations
35
How should patients receiving UFH, LMWH or Rivaroxaban be monitored?
UFH - Anti-Xa acitvity, target 0.35-0.7 LMWH - insufficient evidence to make recommendations but if Anti-Xa activity used - target 0.5-1 Rivaroxaban - no recommendations made
36
What is the recommendation for stopping antiplatelet agents before a invasive procedure in high risk versus low to moderate risk patients?
High risk * if single agent used - don't stop * if 2 agents used - stop one Low to moderate risk * stop 5-7 days before procedure
37
What is the recommendation for discontinuing heparins before an invasive procedure in high risk or low/moderate risk patients?
High risk * don't discontinue * perform surgery at nadir of dose (i.e., when cc lowest) Low/moderate risk * consider stopping LMWH or weaning UFH
38
What is the recommendation for thrombolysis in ATE or VTE in dogs?
ATE * consider thrombolysis in ACUTE, especially if catheter directed therapy available and within 1 hour of thrombosis * not enough evidence for recommendations on chronic ATE VTE * can consider in acute * not enough evidence for chronic Recommend adding anticoagulants or antithrombotics where risk factors for clotting are present
39
What is the recommendation for thrombolysis in ATE or VTE in cats?
ATE * consider thrombolysis if given within 6 hours of thrombosis following risk benefit assessment * no recommendation on catheter directed versus systemic VTE * consider if acute (< 6 hours) if confirmed ATE - consider concurrent anticoagulant and antiplatelet agents